Evaluate reports that total prescription drug sales are projected to reach $1.75 trillion by 2030, with GLP-1 receptor agonists constituting 9% of prescriptions. Eli Lilly's tirzepatide is forecasted to generate $62 billion annually, surpassing the sales peak of Humira and doubling Merck's Keytruda sales. Despite early manufacturing challenges faced by competitor Novo Nordisk, its semaglutide and pipeline candidate CagriSema remain significant players. Lilly’s dual-indication drugs Mounjaro and Zepbound are positioned as market leaders in diabetes and weight loss, underscoring Lilly’s dominance in the GLP-1 space.